TY - JOUR
T1 - Mapping Research on miRNAs in Cancer
T2 - A Global Data Analysis and Bibliometric Profiling Analysis
AU - Shaw, Peter
AU - Lokhotiya, Kartik
AU - Kumarasamy, Chellan
AU - Sunil, Krishnan
AU - Suresh, Deepa
AU - Shetty, Sameep
AU - Muthukaliannan, Gothandam Kodiveri
AU - Baxi, Siddhartha
AU - Mani, Ravishankar Ram
AU - Sivanandy, Palanisamy
AU - Chandramoorthy, Harish
AU - Gupta, Madan Mohan
AU - Samiappan, Suja
AU - Jayaraj, Rama
N1 - Funding Information:
National Research Foundation of Korea (NRF)
Funding Information:
National Basic Research Program of China (973 Program)
Funding Information:
National Natural Science Foundation of China (NSFC)
Funding Information:
Funding: Funded in part by the National Institutes of Health (NIH)/National Institute of Dental and Craniofacial Research (NIDCR) R01DE028105 grant to K.S. Peter Shaw was supported in part by the Jiangsu province, China, 100 Talent project fund (BX2020100) Deanship of Scientific Research, King Khalid University, Abha, Saudi Arabia. Funding #G.R.P 2/27/40 (HCC).
Funding Information:
Natural Science Foundation of Jiangsu Province
Publisher Copyright:
© 2022 by the authors.
PY - 2022/3
Y1 - 2022/3
N2 - miRNAs biomarkers are emerging as an essential part of clinical oncology. Their oncogenic and tumour suppressor properties playing a role in malignancy has generated interest in their potential for use in disease prognosis. While several studies on miRNA have been carried out across the globe, evaluating the clinical implications of miRNAs in cancer diagnosis and prognosis research has currently not been attempted. A study delineating the area of miRNA research, including the topics presently being focused on, the seminal papers in this field, and the direction of research interest, does not exist. This study aims to conduct a large‐scale, global data analysis and bibliometric profiling analysis of studies to evaluate the research output of clinical implications of miR‐ NAs in cancer diagnosis and prognosis listed in the SCOPUS database. A systematic search strategy was followed to identify and extract all relevant studies, subsequently analysed to generate a bibliometric map. SPSS software was used to calculate bibliometric indicators or parameters for analysis, such as year and country of affiliation with leading authors, journals, and institutions. It is also used to analyse annual research outputs, including total citations and the number of times it has been cited with productive nations and H‐index. The number of global research articles retrieved for miRNA‐Cancer research over the study period 2003 to 2019 was 18,636. Between 2012 and 2019, the growth rate of global publications is six times (n = 15,959; 90.71 percent articles) that of 2003 to 2011. (2704; 9.29 per cent articles). China published the most publications in the field of miRNA in cancer (n = 7782; 41%), while the United States had the most citations (n = 327,538; 48%) during the time span. Of these journals, Oncotarget has the highest percentage of article publications. The journal Cancer Research had the most citations (n = 41,876), with 6.20 per cent (n = 41,876). This study revealed a wide variety of journals in which miRNA‐Cancer research are published; these bibliometric parameters exhibit crucial clinical information on performance assessment of research productivity and quality of research output. Therefore, this study provides a helpful reference for clinical oncologists, cancer scientists, policy decision‐makers and clinical data researchers.
AB - miRNAs biomarkers are emerging as an essential part of clinical oncology. Their oncogenic and tumour suppressor properties playing a role in malignancy has generated interest in their potential for use in disease prognosis. While several studies on miRNA have been carried out across the globe, evaluating the clinical implications of miRNAs in cancer diagnosis and prognosis research has currently not been attempted. A study delineating the area of miRNA research, including the topics presently being focused on, the seminal papers in this field, and the direction of research interest, does not exist. This study aims to conduct a large‐scale, global data analysis and bibliometric profiling analysis of studies to evaluate the research output of clinical implications of miR‐ NAs in cancer diagnosis and prognosis listed in the SCOPUS database. A systematic search strategy was followed to identify and extract all relevant studies, subsequently analysed to generate a bibliometric map. SPSS software was used to calculate bibliometric indicators or parameters for analysis, such as year and country of affiliation with leading authors, journals, and institutions. It is also used to analyse annual research outputs, including total citations and the number of times it has been cited with productive nations and H‐index. The number of global research articles retrieved for miRNA‐Cancer research over the study period 2003 to 2019 was 18,636. Between 2012 and 2019, the growth rate of global publications is six times (n = 15,959; 90.71 percent articles) that of 2003 to 2011. (2704; 9.29 per cent articles). China published the most publications in the field of miRNA in cancer (n = 7782; 41%), while the United States had the most citations (n = 327,538; 48%) during the time span. Of these journals, Oncotarget has the highest percentage of article publications. The journal Cancer Research had the most citations (n = 41,876), with 6.20 per cent (n = 41,876). This study revealed a wide variety of journals in which miRNA‐Cancer research are published; these bibliometric parameters exhibit crucial clinical information on performance assessment of research productivity and quality of research output. Therefore, this study provides a helpful reference for clinical oncologists, cancer scientists, policy decision‐makers and clinical data researchers.
UR - http://www.scopus.com/inward/record.url?scp=85125574059&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85125574059&partnerID=8YFLogxK
U2 - 10.3390/pathophysiology29010007
DO - 10.3390/pathophysiology29010007
M3 - Article
AN - SCOPUS:85125574059
SN - 0928-4680
VL - 29
SP - 66
EP - 80
JO - Pathophysiology
JF - Pathophysiology
IS - 1
ER -
